header_img4@2x

Academic
approach

Orikami Contact

All our products have gone through a rigorous clinical validation process.

It is important for us to share our findings and insights. Therefore, our clinical studies and publications are listed below.

Study overview

In the table, you can find an overview of all our current self-initiated clinical studies. Next to these studies, we also participate in multiple partner studies.

Want to know more about a study? Click on the study in the table and you’ll be redirected to the study details.

Studies

Prompt (PD)

Goal

 To explore and develop an algorithm for detection and prediction of Freezing of Gait episodes using smartphones and pressure sensing insoles.

Study group

N= 30 Persons with Parkinson Disease, data collection in lab setting and at home. Collaboration with University of Twente and Radboud University.

Planning

Data collection ongoing.

 

This study is funded by (OP) ERDF East Netherlands.

 

MSSM (MS)

Goal

In this study the primary aim is to evaluate the effectiveness, in terms of self-efficacy control and quality of life, and the cost-effectiveness of self-monitoring based management of MS through the use of the MS sherpa app compared to care as usual without MS sherpa.

Study group

N=225, 125 intervention group, 100 control group, collaboration with Amsterdam UMC, 3 STZ hospitals, MS4Research institute and the Radboud University.

Planning

Planned submission to METC: August 31, 2021.

 

This study is funded by Nationaal MS Fonds and NWO.

APPS MS (MS)

Goal

Develop and explore measuring methods using built-in sensors of conventional smartphones and wearables to quantify fatigue, disease activity and progression in a day-to-day setting in patients with MS.

Study group

N=125, 100 persons with MS, 25 healthy controls, collaboration with Amsterdam UMC, last patient visited in February 2021.

Planning

In data analysis phase, scientific publications in preparation.

MS SELF (MS)

Goal

The aim of this study is to assess the validity, sensitivity and ease of use of new mobile self-monitoring tools for people with Relapsing-Remitting Multiple Sclerosis.

Study group

N= 25 MS patients, N= 79 healthy controls.

Planning

Completed.